|
Código del ensayo medOPP545_ADELA |
|
Ensayo A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors. (The ADELA Study) |
|
Estado Abierto a inclusión |
|
Localización Tumoral Mama |
|
Tipo de ensayo Ensayo de Fase III |
|
Tipo de tratamiento |
|
Situación clínica |
|
Centro |
